EGFR and papilloma: The superior efficacy of Gefitinib compared to Lapatinib suggests that EGFR signaling may be the predominant driver of tumorigenesis in this model, consistent with our observation that p-EGFR was the most strongly upregulated phospho-receptor in Tpl2−/− papillomas.